


# Stabilis



## Mannitol



Tradename

Deltamannit	Germany
Demannitol	Peru
Ecobrain	Peru
Gravert	India
Isotol	Italy
Manitol	Ecuador, Mexico, Peru, Romania, Venezuela
Mannit	Austria, Germany
Mannitol	Canada, Denmark, Egypt, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Ireland, Luxembourg, Norway, Poland, Saudi Arabia, Sweden, Switzerland, Tunisia, Turkey, United Arab Emirates, United States of America
Osmitrol	Australia, Canada, Saudi Arabia, United States of America
Osmofundin	Austria, Luxembourg
Osmorin	Ecuador
Osmosteril	Austria, Germany, Luxembourg
Staloral	Saudi Arabia

















































































### Stability of mixtures

		18,75 mg/ml	-15°C		Magnesium sulfate : 1 & 2 mg/ml Cisplatin : 0,05 & 0,2 mg/ml	30	1080
		18,75 mg/ml	25°C		Magnesium sulfate : 1 & 2 mg/ml Cisplatin : 0,05 & 0,2 mg/ml	48	1080
		18,75 mg/ml	4°C		Cisplatin : 0,05 & 0,2 mg/ml Magnesium sulfate : 1 & 2 mg/ml	4	1080
		200 mg/ml	25°C		Fluorouracil : 1 & 2 mg/ml	24	411



## Compatibility

			
<input checked="" type="checkbox"/>	Mannitol : 150 mg/ml Allopurinol sodium : 3 mg/ml		307
<input checked="" type="checkbox"/>	Mannitol : 150 mg/ml Amifostine : 10 mg/ml		3
	<input checked="" type="checkbox"/> Mannitol Amoxicillin sodium / clavulanic acid		3545
<input checked="" type="checkbox"/>	Mannitol : 250 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
<input checked="" type="checkbox"/>	Mannitol : 150 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
<input checked="" type="checkbox"/>	Mannitol : 0.15 mg/ml Aztreonam : 40 mg/ml		99
<input checked="" type="checkbox"/>	Mannitol : 150 mg/ml Bivalirudin : 5 mg/ml		1713
<input checked="" type="checkbox"/>	Mannitol : 250 mg/ml Caffeine : 10 mg/ml		3964
	<input checked="" type="checkbox"/> Mannitol : 100 & 200 mg/ml Cefamandole nafate		1165
<input checked="" type="checkbox"/>	Mannitol : 200 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
<input checked="" type="checkbox"/>	Mannitol : 150 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
<input checked="" type="checkbox"/>	Mannitol : 150 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
<input checked="" type="checkbox"/>	Mannitol : 150 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
<input checked="" type="checkbox"/>	Mannitol : 150 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
<input checked="" type="checkbox"/>	Mannitol : 250 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
<input checked="" type="checkbox"/>	Mannitol : 150 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
<input checked="" type="checkbox"/>	Mannitol : 150 mg/ml Cladribine : 0.015 mg/ml		1496
<input checked="" type="checkbox"/>	Mannitol : 150 mg/ml Cladribine : 0.5 mg/ml		1496
<input checked="" type="checkbox"/>	Mannitol : 250 mg/ml Cloxacillin sodium : 100 mg/ml		3012
<input checked="" type="checkbox"/>	Mannitol : 20 mg/ml Dopamine hydrochloride : 0.8 mg/ml		732
<input checked="" type="checkbox"/>	Mannitol : 200 mg/ml Fluorouracil : 1 & 2 mg/ml		411
<input checked="" type="checkbox"/>	Mannitol : 200 mg/ml Fosfomycin : 30 mg/ml		4055
<input checked="" type="checkbox"/>	Mannitol : 250 mg/ml Gallium nitrate : 1 mg/ml		91
<input checked="" type="checkbox"/>	Mannitol : 250 mg/ml	RL	4603

		Mannitol : 150 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Mannitol : 150 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Mannitol : 150 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Mannitol : 150 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Mannitol : 150 mg/ml		1415
		Mannitol : 150 mg/ml Doripenem : 5 mg/ml		2262
		Mannitol : 100 & 200 mg/ml Ertapenem : 10 & 20 mg/ml		1906
		Mannitol : 200 mg/ml Furosemide : 10 mg/ml		3823
		Mannitol : 150 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Mannitol : 150 mg/ml		301
		Mannitol : 150 mg/ml Filgrastim : 30 µg/ml		244
		Mannitol : 150 mg/ml Hetastarch : 60 mg/ml		1721
		Mannitol : 12.5 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Mannitol : 200 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Mannitol : 150 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Mannitol : 150 mg/ml Linezolid : 2 mg/ml		1925
		Mannitol : 150 mg/ml Melphalan : 0.1 mg/ml		169
		Mannitol : 250 mg/ml Meropenem : 50 mg/ml		4319
		Mannitol : 250 mg/ml N-acetylcysteine : 200 mg/ml		3766
		Mannitol : 250 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Mannitol : 150 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Mannitol : 150 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Mannitol : 150 mg/ml Paclitaxel : 1.2 mg/ml		248
		Mannitol : 150 mg/ml Palonosetron hydrochloride : 50 µg/ml		2281
		Mannitol Pantoprazole sodium		2090
		Mannitol : 250 mg/ml Paracetamol : 10 mg/ml		4742
		Mannitol : 150 mg/ml Pemetrexed disodium : 20 mg/ml		1953

	Mannitol : 200 mg/ml Phenytoin sodium : 5 mg/ml		3315
	Mannitol : 150 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
	Mannitol : 200 mg/ml Plazomicin sulfate : 24 mg/ml		4145
	Mannitol : 20 mg/ml Potassium chloride : 10000 & 40000 mEq/l		1906
	Mannitol : 150 mg/ml Propofol : 10 mg/ml		300
	Mannitol : 150 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
	Mannitol : 150 mg/ml Sargramostim : 10 µg/ml		335
	Mannitol : 25 mg/ml Sodium bicarbonate : 3.75 mg/ml		322
	Mannitol : 25 mg/ml Sodium bicarbonate : 37,39 mg/ml		298
	Mannitol : 25 mg/ml Sodium bicarbonate : 3.75 mg/ml	RL	322
	Mannitol : 25 mg/ml Sodium bicarbonate : 3.75 mg/ml		322
	Mannitol : 25 mg/ml Sodium bicarbonate : 3.75 mg/ml		322
	Mannitol : 25 mg/ml Sodium bicarbonate : 37,39 mg/ml		298
	Mannitol : 200 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
	Mannitol : 200 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
	Mannitol : 200 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
	Mannitol : 150 mg/ml Teniposide : 0.1 mg/ml		905
			3823
	Mannitol : 200 mg/ml Thiopental sodium : 60 mg/ml		3823
	Mannitol : 150 mg/ml Thiotepa : 1 mg/ml		249
	Mannitol : 20 mg/ml Tramadol hydrochloride : 0,4 mg/ml		2002
	Mannitol : 150 mg/ml Valproic acid : 2 & 20 mg/ml		4428
	Mannitol : 200 mg/ml Valproic acid : 16 mg/ml		3823
	Mannitol : 0.025 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
	Mannitol : 150 mg/ml Vinorelbine tartrate : 1 mg/ml		84



## Route of administration



## References

	Type	Publication
3	Journal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Journal	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81	Journal	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Journal	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Journal	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Journal	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Journal	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Journal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
298	Journal	Matuschka PR, Smith WR, Vissing RS. Compatibility of mannitol and sodium bicarbonate in injectable fluids. Am J Health-Syst Pharm 1995 ; 52: 320-321.
299	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.

300	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Journal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Journal	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
322	Journal	Matuschka PR, Hill LJ. More on compatibility of mannitol and sodium bicarbonate in injectable fluids. Am J Health-Syst Pharm 1996 ; 53: 2639.
334	Journal	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Journal	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
411	Journal	Woloschuk DMM, Wermeling JR, Pruemer JM. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 2158-2160.
491	Journal	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Journal	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
732	Journal	Gardella LA, Zaroslinski JF, Possley LH. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 1: Stability with common intravenous fluids. Am J Hosp Pharm 1975 ; 32: 575-578.
905	Journal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Journal	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1057	Journal	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1080	Journal	La Folette JM, Arbus MH, Lauper RD. Stability of cisplatin admixtures in polyvinyl chloride bags. Am J Hosp Pharm 1985 ; 42: 2652.
1165	Journal	Bowtle WJ, Heasman MJ, Prince AP, Easthope DA. Compatibility of the cephalosporin, cefamandole nafate with injections. Int J Pharm 1980 ; 4: 263-265.
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.

1415	Journal	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Journal	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Journal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Journal	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1713	Journal	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Journal	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	Journal	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1906	Journal	McQuade MS, Van Nostrand V, Shariter J, Kanike JD, Forsyth RJ. Stability and compatibility of reconstituted ertapenem with commonly used iv infusion and coinfusion solutions. Am J Health-Syst Pharm 2004 ; 61: 38-45.
1925	Journal	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Journal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2002	Journal	Abanmy NO, Zaghoul IY, Radwan MA. Compatibility of tramadol hydrochloride injection with selected drugs and solutions. Am J Health-Syst Pharm 2005 ; 62: 1299-1302.
2090	Journal	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2262	Journal	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Journal	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocartil with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2281	Journal	Ben M, Kupiec T, Trusley C, Trisel LA. Compatibility and stability of palonosetron hydrochloride with lactated Ringer's, Hetastarch in lactated electrolyte, an mannitol injections during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 5: 460-462.
3012	Journal	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.











































3249	Journal	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Journal	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3315	Poster	Louvrier M, Dhennain S, Hocahrt S, Zawadski E, Bouffart S, Moquay E. Mise en évidence d'une incompatibilité physico-chimique entre la phénytoïne sodique et le paracétamol injectable en flacon. Communication orale Hopipharm 2012
3408	Journal	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3545	Manufacturer	Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009
3766	Journal	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3823	Journal	Juan E.P, Palau M.M, Cerdá S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs  Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Journal	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	Journal	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Journal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Journal	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Journal	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4428	Journal	Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.



4528	Journal	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Journal	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Journal	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.



# Dictionary

 Various	 Injection
 Tradename	 Stability of mixtures
 Container	 Solvent
 Concentration	 Temperature
 Storage	 Compound
 Duration of stability	 References
 Polyvinyl chloride	 Glucose 5%
 Protect from light	 Day
 Not specified	 Hour
 Polypropylen Syringe	 Sodium chloride 0,9%
 Light	 Compatibility
 Compatible	 Unspecified incompatibility
 Incompatible	 None
 NaCl 0,9% or Glucose 5%	<b>RL</b> Ringer's lactate solution
 NaCl 0,9% + antibacterial	 Water for Injection
 Loss of turbidity	 Parenteral nutrition (with lipids)
 Chemical instability	 Parenteral nutrition (binary mixture)
 Immediate precipitation	 Specific solvent
 NaCl 0,45% Glucose 5%	 Glucose 10%
 Sodium chloride 0,45%	 Route of administration
 Intravenous infusion	 References
 Dictionary	